Literature DB >> 20383482

[Update hyperthyreoidism].

L Möller1, K Mann.   

Abstract

Hyperthyroidism is mainly caused by Graves' disease and toxic adenoma or multinodular goiter. In Europe, treatment of both disorders is usually started with antithyroidal drugs such as methimazole. Complications include agranulocytosis and the risk is dose-dependent. The starting dose of methimazole should not exceed 15-20 mg/d. Propylthiouracil can cause severe liver failure, leading to liver transplantation or death. Propylthiouracil, therefore, should not be used as first line agent and is only recommended when an antithyroid drug is to be started during the first trimester of pregnancy or in individuals who have experienced adverse responses to methimazole. Toxic adenoma is finally treated with radioioidine. To reduce the risk of treatment failure, antithyroidal drugs should be stopped at least one week prior to radioiodine. For Graves' disease, remission is unlikely if antibodies against the TSH-receptor remain above 10 mU/l after 6 months of antithyroidal treatment and radioiodine or thyroidectomy can be recommended. Thyroidectomy should be performed as (near) total thyreoidectomy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20383482     DOI: 10.1007/s00108-009-2496-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  35 in total

1.  Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials.

Authors:  Martin A Walter; Matthias Briel; Mirjam Christ-Crain; Steen J Bonnema; John Connell; David S Cooper; Heiner C Bucher; Jan Müller-Brand; Beat Müller
Journal:  BMJ       Date:  2007-02-19

2.  Atrial fibrillation: Dronedarone and amiodarone-the safety versus efficacy debate.

Authors:  Eric N Prystowsky
Journal:  Nat Rev Cardiol       Date:  2010-01       Impact factor: 32.419

3.  Treatment of hyperthyroidism with a small single daily dose of methimazole.

Authors:  A Shiroozu; K Okamura; H Ikenoue; K Sato; T Nakashima; M Yoshinari; M Fujishima; T Yoshizumi
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

4.  Thyroid arterial embolization to treat Graves' disease.

Authors:  W Zhao; B-L Gao; H-Y Yang; H Li; D-P Song; S-T Xiang; J Shen
Journal:  Acta Radiol       Date:  2007-03       Impact factor: 1.990

5.  Arterial embolization: a novel approach to thyroid ablative therapy for Graves' disease.

Authors:  Haipeng Xiao; Wenquan Zhuang; Shenming Wang; Binjie Yu; Guorui Chen; Muheng Zhou; Norman C W Wong
Journal:  J Clin Endocrinol Metab       Date:  2002-08       Impact factor: 5.958

6.  The relationship between premature ejaculation and hyperthyroidism.

Authors:  Ahmet Cihan; Omer Demir; Tevfik Demir; Guven Aslan; Abdurrahman Comlekci; Adil Esen
Journal:  J Urol       Date:  2009-01-29       Impact factor: 7.450

7.  Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat?

Authors:  Gerasimos E Krassas; Kostas Tziomalos; Fotini Papadopoulou; Nikolaos Pontikides; Petros Perros
Journal:  J Clin Endocrinol Metab       Date:  2008-02-12       Impact factor: 5.958

Review 8.  Antithyroid drug regimen for treating Graves' hyperthyroidism.

Authors:  Prakash Abraham; Alison Avenell; Susan C McGeoch; Louise F Clark; John S Bevan
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

9.  Prevention of relapse of Graves' disease by treatment with an intrathyroid injection of dexamethasone.

Authors:  Xiao-Ming Mao; Hui-Qin Li; Qian Li; Dong-Mei Li; Xiao-Jing Xie; Guo-Ping Yin; Peng Zhang; Xiang-Hong Xu; Jin-Dan Wu; Song-Wang Chen; Shu-Kui Wang
Journal:  J Clin Endocrinol Metab       Date:  2009-10-22       Impact factor: 5.958

Review 10.  Surgical treatment of Graves' disease: evidence-based approach.

Authors:  Peter Stålberg; Anna Svensson; Ola Hessman; Göran Akerström; Per Hellman
Journal:  World J Surg       Date:  2008-07       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.